New update updates on Anaphylaxis management
Reading File
Searching PubMed
anaphylaxis management guidelines
Searching the Web
anaphylaxis management guidelines 2024 2025 updates
Finding Sources
Reading Article
PMID: 39254667
Reading Article
PMID: 41701644
Reading Web Page
https://downloads.regulations.gov/FDA-2025-N-2976-0009/attac…
Reading File
Reading File
Reading File
Reading File
Reading File
Searching PubMed
anaphylaxis epinephrine autoinjector observation discharge biphasic
Reading File
I now have comprehensive information to provide a thorough, up-to-date answer. Let me compile everything.
Anaphylaxis Management: Updated Guidelines (2023-2026)
Key Guideline Updates
The most significant recent update is the 2023 AAAAI/ACAAI Joint Task Force on Practice Parameters (JTFPP) Anaphylaxis Practice Parameter, with further pearls published in 2025 (PMID: 39254667). This supersedes earlier guidance. Here is a full breakdown.
1. Diagnosis Criteria
Anaphylaxis remains a clinical diagnosis. The WAO/NIAID criteria define it as highly likely when any ONE of these two is met:
- Criterion 1: Acute onset of illness with skin/mucosal involvement AND at least one of: respiratory compromise, reduced BP/end-organ dysfunction
- Criterion 2: Two or more of the following after likely allergen exposure: skin/mucosal symptoms, respiratory compromise, reduced BP, persistent GI symptoms
The 2023 JTFPP emphasizes that diagnostic certainty should NEVER delay epinephrine - treat on suspicion.
2. First-Line Treatment: Epinephrine (Adrenaline)
Still the cornerstone - no change here, but emphasis strengthened
| Parameter | Recommendation |
|---|---|
| Drug | Epinephrine 1:1,000 (1 mg/mL) |
| Route | Intramuscular (IM) into the anterolateral mid-thigh - faster absorption than deltoid |
| Adult dose | 0.3-0.5 mg IM |
| Pediatric dose | 0.01 mg/kg IM (max 0.5 mg) |
| Repeat | Every 5 minutes if no improvement |
New from 2023 JTFPP - Pediatric autoinjector dosing update:
- Children <15 kg: Clinician may prescribe either 0.1 mg OR 0.15 mg autoinjector (previously 0.15 mg only)
- Children 15-25 kg: 0.15 mg autoinjector
- Children ≥25 kg: 0.3 mg autoinjector (threshold lowered from 30 kg)
- Adults >50 kg: 0.3 mg or 0.5 mg
Cross-guideline consensus (AAAAI/ACAAI, EAACI, Resuscitation Council UK, 2025 FDA document):
"Immediate epinephrine - without waiting for diagnostic certainty - is the standard of care and the strongest predictor of survival."
A 2026 systematic review (PMID: 41701644, 28 studies, 20 countries) confirmed that delayed epinephrine >30 minutes after symptom onset was consistently associated with fatal outcomes.
3. Positioning
Updated emphasis: Lay the patient flat with legs elevated (supine position). If breathing difficulty is present, allow semi-reclined with legs elevated. Do not allow the patient to stand up suddenly - "fatal posture" (upright or sudden standing) is an independent risk factor for death as it exacerbates hemodynamic collapse.
4. Adjunct Treatments (Second-Line Only)
IV Fluids
- Adults: 1-2 L normal saline rapidly via large-bore IV (16G)
- Pediatrics: 20-30 mL/kg boluses
- Large volumes (up to 2-7 L) may be needed; monitor for overload in cardiac/renal patients
Antihistamines (H1 + H2)
- Must NEVER be used as sole or initial treatment
- Helpful only for cutaneous symptoms (urticaria, pruritus, flushing) as adjuncts
- Diphenhydramine 25-50 mg IV/IM (adult); ranitidine/famotidine as H2 blocker
Corticosteroids
- No immediate effect on anaphylaxis
- No strong evidence they prevent biphasic reactions (this is an important 2023 update - previously often given routinely)
- Optional adjunct only; never precede epinephrine
- If used: hydrocortisone 200 mg IV (adult) or methylprednisolone 1-2 mg/kg
Bronchodilators
- Salbutamol (albuterol) via nebulizer for bronchospasm after epinephrine
Glucagon (special circumstance)
- For patients on beta-blockers who fail to respond to epinephrine
- Adult dose: 1-5 mg IV followed by infusion 5-15 mcg/min
- Pediatric: 20-30 mcg/kg (max 1 mg)
- Pre-medicate with antiemetic (nausea/vomiting common)
5. Refractory Anaphylaxis
If no response after 2+ doses of IM epinephrine:
- IV epinephrine infusion: 0.1-1 mcg/kg/min, titrate to response
- Vasopressors (norepinephrine, vasopressin, methoxamine) if epinephrine infusion fails
- Methylene blue: Considered for refractory vasodilatory shock
- Consider intubation early if airway compromise is progressing
6. Beta-Blocker / ACE Inhibitor Interactions (2023 JTFPP Update)
Important new stance: For patients who require beta-blockers or ACE inhibitors for cardiac disease, the 2023 JTFPP now states:
"Discontinuing or changing beta-blockers and/or ACE inhibitors may pose a larger risk for worsened cardiovascular disease compared with the risk for severe anaphylaxis with medication continuation."
This is a shift from the older blanket recommendation to stop these drugs. Shared decision-making is now emphasized.
7. Observation & Discharge (Updated Criteria)
| Category | Observation Period |
|---|---|
| Mild-moderate, complete symptom resolution, 1 dose epinephrine | Minimum 1 hour (with caregiver comfort and EMS access) |
| Standard risk | 4-6 hours |
| High risk for biphasic reaction | 6+ hours or hospitalize |
High-risk for biphasic features (admit or extend observation):
- Hypotension or wide pulse pressure at presentation
- Unknown trigger
-
1 dose of epinephrine required
- Cutaneous involvement
- History of prior anaphylaxis
- Delayed epinephrine administration
- Protracted initial reaction, airway involvement, or poor social support
Key 2023 update: EMS activation may not be required in patients who experience prompt, complete symptom resolution after epinephrine and caregivers are comfortable with observation at home. This represents a more flexible community-management approach.
8. Predictors of Fatal Anaphylaxis (2026 Systematic Review - PMID: 41701644)
From 28 studies across 20 countries:
- Asthma (most consistent comorbidity)
- Cardiovascular comorbidities
- Age ≥65 years
- Delayed epinephrine (>30 min from symptom onset or absent prehospital)
- Trigger-specific: peanuts and cow's milk in children; perioperative medications in older adults
Real-world data shows only ~41% of patients who carry an epinephrine autoinjector actually use it during a reaction - a major ongoing patient education target.
9. Discharge Planning (All Guidelines Agree)
Every patient discharged must receive:
- Prescription for 2 epinephrine autoinjectors (carry two at all times)
- Written action plan (ASCIA/ACAAI format)
- Education on trigger avoidance, recognition, and when to use autoinjector
- Referral to allergist/immunologist for formal evaluation and immunotherapy if appropriate (e.g., venom allergy, milk/egg allergy - OIT options available)
- Medical alert identification recommended
10. Novel/Emerging Therapies (2025+)
- Omalizumab (anti-IgE): Now being used in select patients to reduce risk of severe community anaphylaxis, particularly for food allergy and chronic spontaneous urticaria
- Oral immunotherapy (OIT): Expanding for peanut, milk, and tree nut - reduces severity of accidental exposure reactions
- Sublingual immunotherapy (SLIT): Growing evidence base for food allergens
- Alpha-gal syndrome: Increasingly recognized trigger (tick-sensitized meat allergy) - guidelines now include this in differential
Summary of What's Changed vs. Older Guidelines
| Area | Old Guidance | 2023-2026 Update |
|---|---|---|
| Pediatric autoinjector <15 kg | 0.15 mg only | 0.1 mg OR 0.15 mg acceptable |
| Pediatric ≥25 kg threshold | ≥30 kg for 0.3 mg | Lowered to ≥25 kg |
| Corticosteroids for biphasic prevention | Routinely given | Not strongly supported; optional only |
| Beta-blocker/ACEi continuation | Often stopped | Continue if cardiac risk of stopping > anaphylaxis risk |
| Minimum observation (mild/resolved) | 4-6 hours | 1 hour may be sufficient in low-risk with resolved symptoms |
| EMS activation after resolution | Always required | Not mandatory if prompt resolution and caregiver comfort |
Sources:
- Rosen's Emergency Medicine, 9e, pp. 2386-2394
- Goldman-Cecil Medicine, International Ed., pp. 2697-2700
- 2023 JTFPP Anaphylaxis Practice Parameter (PMID: 39254667)
- Predictors of Fatal Anaphylaxis systematic review, 2026 (PMID: 41701644)
- FDA/AAAAI/ACAAI/EAACI/Resuscitation Council UK consensus document, Nov 2025
This is a shared conversation. Sign in to Orris to start your own chat.